Harmony Biosciences Holdings (HRMY)vsInsmed Inc (INSM)
HRMY
Harmony Biosciences Holdings
$27.59
+1.81%
HEALTHCARE · Cap: $1.60B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Harmony Biosciences Holdings generates 43% more annual revenue ($868.45M vs $606.42M). HRMY leads profitability with a 18.3% profit margin vs -2.1%. HRMY earns a higher WallStSmart Score of 62/100 (C+).
HRMY
Buy62
out of 100
Grade: C+
INSM
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-98.5%
Fair Value
$18.43
Current Price
$27.59
$9.16 premium
Intrinsic value data unavailable for INSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Safe zone — low bankruptcy risk
Every $100 of equity generates 21 in profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 21.1% year-over-year
No standout strengths identified
Areas to Watch
Smaller company, higher risk/reward
Earnings declined 55.0%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HRMY
The strongest argument for HRMY centers on P/E Ratio, Altman Z-Score, Return on Equity. Profitability is solid with margins at 18.3% and operating margin at 15.8%. Revenue growth of 21.1% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : HRMY
The primary concerns for HRMY are Market Cap, EPS Growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
HRMY profiles as a growth stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
HRMY is growing revenue faster at 21.1% — sustainability is the question.
HRMY generates stronger free cash flow (126M), providing more financial flexibility.
Bottom Line
HRMY scores higher overall (62/100 vs 39/100), backed by strong 18.3% margins and 21.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harmony Biosciences Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?